Suppr超能文献

从糖尿病前期进展为 2 型糖尿病的葡萄糖代谢受损和最终进展的终身风险:一项前瞻性队列研究。

Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study.

机构信息

Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands.

Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands; Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands.

出版信息

Lancet Diabetes Endocrinol. 2016 Jan;4(1):44-51. doi: 10.1016/S2213-8587(15)00362-9. Epub 2015 Nov 11.

Abstract

BACKGROUND

Data are scarce for the lifetime risk of developing impaired glucose metabolism, including prediabetes, as are data for the risk of eventual progression from prediabetes to diabetes and for initiation of insulin treatment in previously untreated patients with diabetes. We aimed to calculate the lifetime risk of the full range of glucose impairments, from normoglycaemia to prediabetes, type 2 diabetes, and eventual insulin use.

METHODS

In this prospective population-based cohort analysis, we used data from the population-based Rotterdam Study. We identified diagnostic events by use of general practitioners' records, hospital discharge letters, pharmacy dispensing data, and serum fasting glucose measurements taken at the study centre (Rotterdam, Netherlands) visits. Normoglycaemia, prediabetes, and diabetes were defined on the basis of WHO criteria for fasting glucose (normoglycaemia: ≤6·0 mmol/L; prediabetes: >6·0 mmol/L and <7·0 mmol/L; and diabetes ≥7·0 mmol/L or use of glucose-lowering drug). We calculated lifetime risk using a modified version of survival analysis adjusted for the competing risk of death. We also estimated the lifetime risk of progression from prediabetes to overt diabetes and from diabetes free of insulin treatment to insulin use. Additionally, we calculated years lived with healthy glucose metabolism.

FINDINGS

We used data from 10 050 participants from the Rotterdam Study. During a follow-up of up to 14·7 years (between April 1, 1997, and Jan 1, 2012), 1148 participants developed prediabetes, 828 developed diabetes, and 237 started insulin treatment. At age 45 years, the remaining lifetime risk was 48·7% (95% CI 46·2-51·3) for prediabetes, 31·3% (29·3-33·3) for diabetes, and 9·1% (7·8-10·3) for insulin use. In individuals aged 45 years, the lifetime risk to progress from prediabetes to diabetes was 74·0% (95% CI 67·6-80·5), and 49·1% (38·2-60·0) of the individuals with overt diabetes at this age started insulin treatment. The lifetime risks attenuated with advancing age, but increased with increasing BMI and waist circumference. On average, individuals with severe obesity lived 10 fewer years without glucose impairment compared with normal-weight individuals.

INTERPRETATION

Impaired glucose metabolism is a substantial burden on population health, and our findings emphasise the need for more effective prevention strategies, which should be implemented as soon in a person's life as possible. The substantial lifetime risk of prediabetes and diabetes in lean individuals also supports risk factor control in non-obese individuals.

FUNDING

Erasmus MC and Erasmus University Rotterdam; Netherlands Organisation for Scientific Research; Netherlands Organisation for Health Research and Development; Research Institute for Diseases in the Elderly; Netherlands Genomics Initiative; Netherlands Ministry of Education, Culture and Science; Netherlands Ministry of Health, Welfare and Sports; European Commission; and Municipality of Rotterdam.

摘要

背景

目前有关发展为葡萄糖代谢受损(包括糖尿病前期)的终生风险的数据很少,关于从糖尿病前期进展为糖尿病以及未经治疗的糖尿病患者开始胰岛素治疗的最终风险的数据也很少。我们旨在计算从正常血糖到糖尿病前期、2 型糖尿病以及最终胰岛素使用的所有葡萄糖异常的终生风险。

方法

在这项基于人群的前瞻性队列分析中,我们使用了基于人群的鹿特丹研究的数据。我们通过使用全科医生的记录、医院出院记录、药房配药数据以及在研究中心(荷兰鹿特丹)就诊时的血清空腹血糖测量值来确定诊断事件。正常血糖、糖尿病前期和糖尿病是根据世界卫生组织(WHO)的空腹血糖标准定义的(正常血糖:≤6.0mmol/L;糖尿病前期:>6.0mmol/L 且<7.0mmol/L;糖尿病≥7.0mmol/L 或使用降血糖药物)。我们使用经过改良的生存分析来计算终生风险,该分析调整了死亡的竞争风险。我们还估计了从糖尿病前期进展为显性糖尿病以及从无胰岛素治疗的糖尿病进展为胰岛素治疗的终生风险。此外,我们计算了具有健康葡萄糖代谢的年数。

结果

我们使用了来自鹿特丹研究的 10 050 名参与者的数据。在最长 14.7 年的随访期间(1997 年 4 月 1 日至 2012 年 1 月 1 日),有 1148 名参与者发展为糖尿病前期,828 名参与者发展为糖尿病,237 名参与者开始胰岛素治疗。在 45 岁时,剩余的终生风险为糖尿病前期 48.7%(95%CI 46.2-51.3),糖尿病 31.3%(29.3-33.3)和胰岛素使用 9.1%(7.8-10.3)。在 45 岁的个体中,从糖尿病前期进展为糖尿病的终生风险为 74.0%(95%CI 67.6-80.5),在这个年龄患有显性糖尿病的个体中,有 49.1%(38.2-60.0)开始使用胰岛素治疗。随着年龄的增长,终生风险会减弱,但会随着 BMI 和腰围的增加而增加。平均而言,与体重正常的个体相比,严重肥胖的个体葡萄糖代谢异常的寿命平均减少了 10 年。

解释

葡萄糖代谢受损对人群健康构成了重大负担,我们的研究结果强调了需要更有效的预防策略,应尽早在一个人的一生中实施这些策略。在瘦个体中,糖尿病前期和糖尿病的终生风险很大,这也支持在非肥胖个体中控制风险因素。

资助

鹿特丹伊拉斯谟医学中心和鹿特丹伊拉斯谟大学;荷兰科学研究组织;荷兰健康研究与发展组织;老年病学研究协会;荷兰基因组学倡议;荷兰教育部、文化和科学部;荷兰卫生、福利和体育部;欧盟委员会;鹿特丹市。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验